MedTrace Logo

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

NCT00710528 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2012-08-31

No results posted yet for this study

Summary

The purpose of this study is to determine the dose that can be safely given to see what effect it may have on your cancer and to determine how the drug is distributed in the body.

Conditions

  • Chronic Lymphocytic Leukemia (CLL)
  • Lymphoma, Non-Hodgkin (NHL)
  • Acute Myeloid Leukemia (AML)
  • Multiple Myeloma (MM)

Interventions

DRUG

CAL-101

CAL-101 50, 100, 150, 200, 350 mg capsules BID for 28 days CAL-101 150, 300 mg QD for 28 days CAL-101 150 mg BID 3 weeks on 1 week off for 28 days

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2011-12-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00710528 on ClinicalTrials.gov